Please login to the form below

Not currently logged in
Email:
Password:

Clinigen acquires Idis for £225m

Acquisition makes them the global leader in unlicensed medicines

edit-clinigen-big 

Clinigen Group is to acquire unlicensed medicines supplier Idis for £225m.

The ethical unlicensed supply market is estimated to be worth in excess of $5bn and upon completion, Clinigen claims it will become the market leader. 

Peter George, CEO of Clinigen, commented: “This acquisition satisfies a number of our key strategic goals – achieving market leader position in the $5+billion unlicensed medicine supply sector and strengthening our leading position in the $2 billion clinical trial supply market.

“The acquisition will also accelerate our growth and give us a much better balanced portfolio of businesses, whilst extending our unique business model.”

Idis supplies unlicensed medicines predominantly on an exclusive basis through managed access programmes as well as on demand via its general access division.

George concluded: “The enlarged entity creates an incredibly exciting business with tremendous opportunities for growth. I am confident that, together with Idis, we have the right people to define and shape the unlicensed medicine supply market - an increasingly important health care sector for patients with unmet needs.”

Article by
Kirstie Pickering

27th April 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics